Analyst firms · Leerink Partners · BEAM
Leerink Partners BEAM price target and rating history
Beam Therapeutics Inc. (BEAM) · Health Care
Leerink Partners rates Beam Therapeutics Inc. (BEAM) Outperform with a $39 price target, as of its latest action on Nov 6, 2024. It has published 5 rating actions on BEAM since October 2021, including 1 upgrade and 1 downgrade.
- Current rating
- Outperform
- Price target
- $39
- Median target, all firms
- Too few
- Actions on BEAM
- 5
Leerink Partners price target on BEAM
Every Leerink Partners rating on BEAM
- Nov 6, 2024
- Oct 20, 2023
- Jan 10, 2022
- Nov 9, 2021
- Oct 19, 2021
Questions about Leerink Partners and BEAM
- What is Leerink Partners's price target for BEAM?
- Leerink Partners's latest stated price target for Beam Therapeutics Inc. (BEAM) is $39, from its action on Nov 6, 2024.
- What is Leerink Partners's rating on BEAM?
- Leerink Partners rates BEAM Outperform, a bullish rating, as of Nov 6, 2024.
- When did Leerink Partners last change its view on BEAM?
- On Nov 6, 2024, Leerink Partners upgrades to Outperform from Market Perform, price target $27 to $39.
More BEAM rating histories
All Leerink Partners ratingsBEAM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.